Lesley Ann Saketkoo

Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study

Nicola Farina, Silvia Bellando Randone, Hilde Jenssen-Bjørkekjær, Sébastien Sanges et autres

OBJECTIVES: The role of anticoagulation in systemic sclerosis (SSc) with precapillary pulmonary hypertension (PH) remains controversial, with conflicting evidence regarding its impact on survival, including potential harmful effects. Aiming to address this research gap, we evaluated both mortality and PH worsening in …

it, no, us, fr, es, de, nl, il, be, gb, ch, jp, nz, ro, hr, pt, hu, se, br, Afrique du Sud (code pays fourni par la source)

P.188 Optimising the assessment and novel mechanistic insights into digital ulcers in systemic sclerosis: design of the international ‘100 DU’ study

Ashley Seepujak, John Pauling, Marina Anderson, Ami Shah et autres

Introduction Digital ulcers (DU) remain a major cause of disease-related morbidity in systemic sclerosis (SSc). Previous clinical trials of SSc-DU have primarily focussed on clinician assessment of DU occurrence and healing. Previous trials have placed comparatively little emphasis on how patients ‘feel’ …

gb, us, ca, au (code pays fourni par la source)

Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database

Aslihan Avanoglu-Guler, M.I. Hughes, Giacomo De Luca, Silvia Bellando Randone et autres

OBJECTIVES: Calcinosis Cutis (CaC) represents one of the most frequent and disabling non-lethal manifestations in SSc. Our objectives were to evaluate (1) associations of CaC with SSc clinical characteristics and (2) identify risk factors for CaC development. METHODS: EUSTAR database-registered SSc patients …

it, tr, gb, fr, pl, ro, il, de, gr, ch, nl (code pays fourni par la source)

The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)

L. Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, Rucsandra Dobrota et autres

Shared governance of international myositis networks

Teerin Liewluck, Lisa G. Rider, Karen Kow Yip Cheng, Hector Chinoy et autres

Editorial; Authors: T. Liewluck, L.G. Rider, K. Cheng, H. Chinoy, M.M. Dimachkie, E. Dourado, P.C. Gandiga, D.A. Isenberg, K. Ardalan, S. Keret, S. Kim, P. Korsten, I.E. Lundberg, P.M. Machado, F.W. Miller, C. Papadopoulou, S. Rosina, L.A. Saketkoo, S. Schlüter, J. Vencovský, …

us, gb, pt, il, br, de, se, it, cz, nl (code pays fourni par la source)

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis

Urvashi Kaundal, Pei‐Suen Tsou, Mousumi Sahu, Mengqi Huang et autres

OBJECTIVES: Vasculopathy and fibrosis are central to the pathogenesis of systemic sclerosis (SSc) and their genetic underpinnings are largely unknown. Here, we sought to examine the aetiology of severe vascular phenotypes and poorer outcomes in African American (AA) patients with SSc. METHODS: …

us (code pays fourni par la source)

The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)

L. Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, Rucsandra Dobrota et autres

OBJECTIVES: Interstitial lung disease (ILD) carries significant morbidity and mortality risk in systemic sclerosis (SSc). We aimed to estimate the incidence of new-onset SSc-ILD and the associated risk factors, as well as its impact on the prognosis. METHODS: Patients classified as having …

ch, ua, it, nl, fr, de, cz, nz, hr, ro, jp, il, us (code pays fourni par la source)

Establishing Specialized Rare Disease Clinics: Myositis Diseases as an Illustrative Example by the MIHRA Career Enhancement Program

Jasmine Parihar, Meera Shah, Lesley Ann Saketkoo, Latika Gupta

in (code pays fourni par la source)

The Current Status of Exercise Applications as Medicine in Myositis Diseases on Behalf of MIHRA ICERS and MIHRA Clinical Trial Sites Network

Fulden Sarı, Helene Alexanderson, Henrik Pettersson, Ingrid de Groot et autres

se, us (code pays fourni par la source)

Reply

Matthew R. Lammi, Kathleen D. Kolstad, Lesley Ann Saketkoo, Avani Khatri et autres

us, hr (code pays fourni par la source)

Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study

Vincent Sobanski, Jeska de Vries‐Bouwstra, Anna‐Maria Hoffmann‐Vold, Dörte Huscher et autres

OBJECTIVES: This study assessed how changes in lung function, skin fibrosis and digital ulceration (DU) burden predict mortality in patients with SSc-associated interstitial lung disease (SSc-ILD), the leading cause of death in SSc. METHODS: Adult SSc-ILD patients from the European Scleroderma Trials …

fr, nl, no, ch, de, cn, it, Afrique du Sud, hu, pl (code pays fourni par la source)

Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort

Stefano Di Donato, John David Pauling, Sheila Ramjug, Yannick Allanore et autres

OBJECTIVES: Systemic sclerosis (SSc) is characterized by widespread vascular damage resulting in digital and systemic vasculopathic sequelae. Although there are effective treatments available, vascular disease remains a significant cause of morbidity and mortality in SSc. Our aim was to describe patterns of …

fr, gb, it, ru, ro, pt, py, es, br, jp, nl (code pays fourni par la source)